# CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

> **NCT04047303** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 20 (actual)

## Conditions studied

- Astrocytoma
- Glioblastoma

## Interventions

- **DRUG:** CC-90010

## Key facts

- **NCT ID:** NCT04047303
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-02
- **Primary completion:** 2024-06-03
- **Final completion:** 2024-06-03
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Business objectives have changed.
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04047303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04047303, "CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04047303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*